Notice2024-09857
Proposed Data Collection Submitted for Public Comment and Recommendations
Primary source
Metadata and text below are from the Federal Register, a public-domain U.S. government work. Always verify the official published version before relying on it for any legal matter.
Published
May 7, 2024
Issuing agencies
Health and Human Services DepartmentCenters for Disease Control and Prevention
Abstract
The Centers for Disease Control and Prevention (CDC), as part of its continuing effort to reduce public burden and maximize the utility of government information, invites the general public and other federal agencies the opportunity to comment on a proposed and/or continuing information collection, as required by the Paperwork Reduction Act of 1995. This notice invites comment on a proposed information collection project titled Comprehensive Evaluations of the Division for Heart Disease and Stroke Prevention Programs (WISEWOMAN, National CVH Program, Innovative CVH Program). The purpose of the data collection is to evaluate the implementation of evidence-based strategies within these programs, measure their impact on cardiovascular disease (CVD) prevention and management, and to identify strategies that are most effective in reaching populations disproportionately affected by CVD.
Full Text
<html>
<head>
<title>Federal Register, Volume 89 Issue 89 (Tuesday, May 7, 2024)</title>
</head>
<body><pre>
[Federal Register Volume 89, Number 89 (Tuesday, May 7, 2024)]
[Notices]
[Pages 38151-38153]
From the Federal Register Online via the Government Publishing Office [<a href="http://www.gpo.gov">www.gpo.gov</a>]
[FR Doc No: 2024-09857]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
[60Day-24-24FI; Docket No. CDC-2024-0036]
Proposed Data Collection Submitted for Public Comment and
Recommendations
AGENCY: Centers for Disease Control and Prevention (CDC), Department of
Health and Human Services (HHS).
ACTION: Notice with comment period.
-----------------------------------------------------------------------
SUMMARY: The Centers for Disease Control and Prevention (CDC), as part
of its continuing effort to reduce public burden and maximize the
utility of government information, invites the general public and other
federal agencies the opportunity to comment on a proposed and/or
continuing information collection, as required by the Paperwork
Reduction Act of 1995. This notice invites comment on a proposed
information collection project titled Comprehensive Evaluations of the
Division for Heart Disease and Stroke Prevention Programs (WISEWOMAN,
National CVH Program, Innovative CVH Program). The purpose of the data
collection is to evaluate the implementation of evidence-based
strategies within these programs, measure their impact on
cardiovascular disease (CVD) prevention and management, and to identify
strategies that are most effective in reaching populations
disproportionately affected by CVD.
DATES: CDC must receive written comments on or before July 8, 2024.
ADDRESSES: You may submit comments, identified by Docket No. CDC-2024-
0036 by either of the following methods:
<bullet> Federal eRulemaking Portal: <a href="http://www.regulations.gov">www.regulations.gov</a>. Follow
the instructions for submitting comments.
<bullet> Mail: Jeffrey M. Zirger, Information Collection Review
Office, Centers for Disease Control and Prevention, 1600 Clifton Road
NE, MS H21-8, Atlanta, Georgia 30329.
Instructions: All submissions received must include the agency name
and Docket Number. CDC will post, without change, all relevant comments
to <a href="http://www.regulations.gov">www.regulations.gov</a>.
Please note: Submit all comments through the Federal eRulemaking
portal (<a href="http://www.regulations.gov">www.regulations.gov</a>) or by U.S. mail to the address listed
above.
FOR FURTHER INFORMATION CONTACT: To request more information on the
proposed project or to obtain a copy of the information collection plan
and instruments, contact Jeffrey M. Zirger, Information Collection
Review Office, Centers for Disease Control and Prevention, 1600 Clifton
Road NE, MS H21-8, Atlanta, Georgia 30329; Telephone: 404-639-7570;
Email: <a href="/cdn-cgi/l/email-protection#cca3a1ae8cafa8afe2aba3ba"><span class="__cf_email__" data-cfemail="cda2a0af8daea9aee3aaa2bb">[email protected]</span></a>.
SUPPLEMENTARY INFORMATION: Under the Paperwork Reduction Act of 1995
(PRA) (44 U.S.C. 3501-3520), federal agencies must obtain approval from
the Office of Management and Budget (OMB) for each collection of
information they conduct or sponsor. In addition, the PRA also requires
federal agencies to provide a 60-day notice in the Federal Register
concerning each proposed collection of information, including each new
proposed collection, each proposed extension of existing collection of
information, and each reinstatement of previously approved information
collection before submitting the collection to the OMB for approval. To
comply with this requirement, we are publishing this notice of a
proposed data collection as described below.
The OMB is particularly interested in comments that will help:
1. Evaluate whether the proposed collection of information is
necessary for the proper performance of the functions of the agency,
including whether the information will have practical utility;
2. Evaluate the accuracy of the agency's estimate of the burden of
the proposed collection of information, including the validity of the
methodology and assumptions used;
3. Enhance the quality, utility, and clarity of the information to
be collected;
4. Minimize the burden of the collection of information on those
who are to respond, including through the use of appropriate automated,
electronic, mechanical, or other technological collection techniques or
other forms of information technology, e.g., permitting electronic
submissions of responses; and
[[Page 38152]]
5. Assess information collection costs.
Proposed Project
Comprehensive Evaluations of the Division for Heart Disease and
Stroke Prevention Programs (WISEWOMAN, National CVH Program, Innovative
CVH Program)--New--National Center for Chronic Disease Prevention and
Health Promotion (NCCDPHP), Centers for Disease Control and Prevention
(CDC).
Background and Brief Description
The Centers for Disease Control and Prevention (CDC) Division for
Heart Disease and Stroke Prevention (DHDSP) are submitting this new
three-year information collection request (ICR) for an evaluation of
three recently launched cooperative agreements: Well-Integrated
Screening of Women Across the Nation (WISEWOMAN), The National
Cardiovascular Health Program (The National CVH Program), and The
Innovative Cardiovascular Health Program (The Innovative CVH Program).
The WISEWOMAN program supports the early detection and treatment of
hypertension in low-income, uninsured, and underinsured participants,
ages 35-64. The National CVH Program implements evidence-based
strategies to manage CVD in populations impacted by the high prevalence
of CVD, exacerbated by health inequities and disparities, emphasizing
hypertension and high cholesterol control among adults aged 18-85. The
Innovative CVH Program focuses on implementing innovative evidence-
based strategies to assess and address the health disparities and
inequities in communities at highest risk (defined as census tracts
with a crude hypertension prevalence of 53% or higher), where there is
a particular need for equity-focused health system interventions to
prevent, detect, control, and manage hypertension and high cholesterol.
These three programs build upon CDC's previous work to identify
promising CVD prevention and management practices and fund various
organizations, including State and County governments, American Indian
or Alaska Native tribal governments, non-government organizations,
institutions of higher education, to implement evidence-based
strategies in their jurisdictions. Since the programs are a substantial
investment of federal funds, comprehensive evaluations are important to
demonstrate the types of interventions being implemented and what is
being accomplished using these funds.
The comprehensive evaluation of these programs includes process and
outcome evaluations, and a cross-program analysis to assess the unique
contributions of each program towards evidence-based strategies, health
equity advancement, and health system transformation over the five
program years. The evaluation aims to describe the implementation of
the programs, assess the extent to which short-term, intermediate, and
long-term outcomes have been met, and estimate the costs involved in
implementing the programs. The comprehensive evaluation is designed to
complement the evaluations already being conducted by program
recipients. The data collection focuses on obtaining qualitative and
cost information at the organizational and community levels about
strategy implementation, facilitators and barriers, and other
contextual information that affects program implementation and
participant outcomes. Data collection activities of the comprehensive
evaluation include qualitative interviews for evaluability assessments,
exploratory assessments, and cost data collected for a cost study.
During the qualitative data collection, semi-structured interviews will
be conducted with recipients, their partnering sites, and Learning
Collaborative members, providing a multifaceted view of the program's
implementation and outcomes. Cost data will be used to estimate the
implementation costs and value of resources invested by program
recipients and their partners. Cost data will be collected through a
spreadsheet-based cost inventory tool, key informant interviews, and
document reviews. There are no costs to respondents except their time.
Data collection tools are crafted to ensure relevance and capture
essential information needed to evaluate the effectiveness and impact
of the program strategies, while minimizing respondent burden.
The findings from the data collection will provide tailored,
action-oriented, and timely recommendations for program improvement
throughout the program period. Findings will foster documentation and
sharing of lessons learned, contribute to the evidence base, and
support replication and scaling of promising program strategies.
Without collection of evaluative data, CDC will not be able to capture
critical information needed to continuously improve programmatic
efforts and clearly demonstrate the responsible use of federal funds.
CDC requests OMB approval for an estimated 2,054 annual burden
hours. There is no cost to respondents other than their time to
participate.
Estimated Annualized Burden Hours:
----------------------------------------------------------------------------------------------------------------
Number of Average burden
Type of respondents Form name Number of responses per per response Total burden
respondents respondent (in hours) (in hours)
----------------------------------------------------------------------------------------------------------------
Recipients.................... Evaluability 72 1 0.5 36
Assessment
Nomination
Form_NCHP_ICHP.
Evaluability 35 1 0.5 17.5
Assessment
Nomination
Form_WW.
Eval Assessment 18 1 1.5 27
CCL Recipient
Interview Guide
NCHP_ICHP.
Eval Assessment 18 1 1.5 27
CQM Recipient
Interview Guide
NCHP_ICHP.
Eval Assessment 18 1 1.5 27
TBC Recipient
Interview Guide
NCHP_ICHP.
Eval Assessment 8 1 1.5 12
CCL Recipient
Interview Guide
WW.
Eval Assessment 8 1 1.5 12
CQM Recipient
Interview Guide
WW.
Eval Assessment 8 1 1.5 12
TBC Recipient
Interview Guide
WW.
Ex Assessment 4 1 1.5 6
CCL Recipient
Interview
Guide_WW.
[[Page 38153]]
Ex Assessment 4 1 1.5 6
CQM Recipient
Interview
Guide_WW.
Ex Assessment 4 1 1.5 6
TBC Recipient
Partner
Interview
Guide_WW.
Ex Assessment 9 1 1.5 13.5
CCL Recipient
Interview Guide
NCHP_ICHP.
Ex Assessment 9 1 1.5 13.5
CQM Recipient
Interview Guide
NCHP_ICHP.
Ex Assessment 9 1 1.5 13.5
TBC Recipient
Interview Guide
NCHP_ICHP.
Cost Study 165 1 1 165
Interview
Guide_Recipient.
Comprehensive 110 1 2.5 275
Evaluation
Resource Use
and Cost
Inventory
Tool_Recipient.
Eval Assessment 18 1 1.5 27
CCL Partner
Interview Guide
NCHP_ICHP.
Eval Assessment 18 1 1.5 27
CQM Partner
Interview Guide
NCHP_ICHP.
Eval Assessment 18 1 1.5 27
TBC Partner
Interview Guide
NCHP_ICHP.
Eval Assessment 8 1 1.5 12
CCL Partner
Interview Guide
WW.
Eval Assessment 8 1 1.5 12
CQM Partner
Interview Guide
WW.
Eval Assessment 8 1 1.5 12
TBC Partner
Interview Guide
WW.
Ex Assessment 4 1 1.5 6
CCL Partner
Interview
Guide_WW.
Ex Assessment 4 1 1.5 6
CQM Partner
Interview
Guide_WW.
Ex Assessment 4 1 1.5 6
TBC Partner
Interview
Guide_WW.
Ex Assessment 9 1 1.5 13.5
CCL Partner
Interview Guide
NCHP_ICHP.
Ex Assessment 9 1 1.5 13.5
CQM Partner
Interview Guide
NCHP_ICHP.
Ex Assessment 9 1 1.5 13.5
TBC Partner
Interview Guide
NCHP_ICHP.
Comprehensive 330 1 2.5 825
Evaluation
Resource Use
and Cost
Inventory
Tool_Partner.
Cost Study 330 1 1 330
Interview
Guide_Partner.
Learning Collaborative........ Eval Assessment 36 1 1 36
LC Interview
Guide_NCHP_ICHP.
Ex Assessment LC 18 1 1 18
Interview Guide
NCHP_ICHP.
---------------------------------------------------------------
Totals.................... ................ .............. .............. .............. 2054
----------------------------------------------------------------------------------------------------------------
Jeffrey M. Zirger,
Lead, Information Collection Review Office, Office of Public Health
Ethics and Regulations, Office of Science, Centers for Disease Control
and Prevention.
[FR Doc. 2024-09857 Filed 5-6-24; 8:45 am]
BILLING CODE 4163-18-P
</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>Indexed from Federal Register on May 7, 2024.
This is legal information, not legal advice. Laws vary by jurisdiction and change frequently. Always verify current law with official sources and consult a licensed attorney in your jurisdiction for advice on your specific situation.